Page 100 - AN-2-3
P. 100

Advanced Neurology                                                 eGFR and serum neurofilament light chain




            Table 5. Subgroup analysis                         some limitations. First, the cross-sectional design of our
                                                               study limits our ability to establish causality between eGFR,
             Variables    β (95% CI [upper   P‑value  P for
                          limit, lower limit])   interaction   sNfL levels, and hypertension. Longitudinal studies are
            Age (years)                             0.44       needed to better understand the temporal relationship and
                                                               potential causal pathways. Second, our study focused on
             <60         −0.17 (−0.24, −0.10)  <0.01           a specific time frame and the American adult population.
             ≥60          −0.36 (−0.75, 0.04)  0.07            The results may not be fully generalized to other regions or
            Sex                                     0.39       age groups, and variations in health-care systems, genetics,
             Female      −0.17 (−0.27, −0.06)  0.01            and lifestyles should be considered. For further research,
             Male        −0.23 (−0.41, −0.05)  0.02            conducting longitudinal studies with multiple time points
            BMI (kg/m )                             0.21       would allow for tracking changes in all variables, providing
                   2
             <5          −0.17 (−0.30, −0.03)  0.02            more insight into the causal relationship and potential
             25–30        −0.09 (−0.19, 0.01)  0.07            predictive  value.  What’s  more,  comparing  the  utility  of
             ≥30         −0.20 (−0.34, −0.06)  0.01            sNfL with other established biomarkers in assessing kidney
            Hypertension                            0.01       function and neurological damage could provide a broader
                                                               context for the potential clinical applications of sNfL. In
             No          −0.05 (−0.09, −0.01)  0.02            conclusion, our findings emphasize the significance of
             Yes         −0.33 (−0.50, −0.15)  0.01            considering both kidney function and hypertension status
            DM                                      0.45       when evaluating sNfL levels.
             No          −0.14 (−0.26, −0.02)  0.02
             Yes         −0.40 (−0.61, −0.18)  0.01            5. Conclusion
            CKD                                     0.57       Our findings emphasize the significance of considering
             No           −0.15 (−0.33, 0.03)  0.10            both  kidney  function  and hypertension  status  when
             Yes         −0.30 (−0.54, −0.07)  0.01            evaluating sNfL levels. Our research demonstrates a strong
            Abbreviations: BMI: Body mass index; CI: Confidence interval; CKD;   relationship between the eGFR and sNfL. To summarize,
            Chronic kidney disease; DM; Diabetes mellitus.     our study reveals a negative correlation between eGFR and
                                                               sNfL levels in the adult population, with a turning point at
              Moreover, a recent cross-sectional study demonstrated   an eGFR of 59.9. These findings contribute to the growing
            that diabetes was associated with elevated sNfL levels, and   body of literature highlighting the potential utility of sNfL
            this correlation remained significant even after accounting   as a biomarker for kidney function and hypertension-
            for related covariates . Coincidentally, Maalmi  et al.    induced  neurological  damage.  Future  research  could
                                                        [28]
                             [27]
            have also identified sNfL as a potential novel biomarker for   explore whether monitoring sNfL levels facilitates the
            early diabetic sensorimotor polyneuropathy. In light of these   monitoring of kidney disease progression.
            findings, we included diabetes mellitus in our subgroup
            analysis and found no significant interaction with eGFR.   Acknowledgments
            The inclusion of diabetes mellitus in the subgroup analysis   We thanked all the researchers and participants of the
            and the absence of a significant interaction offer valuable   NHANES study for their critical review and profound
            insights. This observation suggests that while diabetes   contributions.
            may contribute to elevated sNfL levels, its interaction with
            eGFR may differ from that of hypertension. This nuanced   Funding
            distinction prompts us to explore the distinct molecular
            pathways through which diabetes impacts neuronal health.   None.
            This distinction holds the potential to tailor interventions
            aimed  at  customizing  neuroprotection  strategies  for   Conflict of interest
            individuals with varying comorbidities.            The author declares that the research was conducted in the
              A recent study has demonstrated that urine sNfL   absence of any commercial or financial relationships that
            could effectively differentiate between individuals with   could be construed as a potential conflicts of interest.
            neuronal damage and those without . This non-invasive   Author contributions
                                         [29]
            and fast detection method could be valuable for detecting
            neurological damage. Nevertheless, our study still has   This is a single-authored article.



            Volume 2 Issue 3 (2023)                         7                         https://doi.org/10.36922/an.1394
   95   96   97   98   99   100   101   102   103   104